Focuses on specialty pharmaceuticals for metabolic disorders and oncology supportive care.
Theratechnologies Inc., a leading biopharmaceutical firm, specializes in advancing and commercializing innovative therapies aimed at addressing critical medical needs across the United States, Canada, and Europe. The company is recognized for its groundbreaking treatments such as EGRIFTA and EGRIFTA SV, which target the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Additionally, Theratechnologies markets Trogarzo, an ibalizumab injection designed specifically for treating HIV-1 patients resistant to multiple drugs.
In addition to its established therapies, Theratechnologies maintains a robust pipeline of potential breakthrough treatments. This includes the F8 Formulation intended to address lipodystrophy in individuals living with HIV, as well as TH1902 currently undergoing Phase 1/Part A clinical trials for the treatment of triple negative breast cancer. Furthermore, the company is advancing TH1904, a promising candidate targeting ovarian cancer.
Founded in 1993 and headquartered in Montreal, Canada, Theratechnologies Inc. has positioned itself at the forefront of biopharmaceutical innovation. With a strong commitment to enhancing patient care through research and development, Theratechnologies continues to expand its portfolio of therapies, striving to make meaningful contributions to the medical community worldwide.